New way to deliver c. diff treatment: through a colonoscopy
NCT ID NCT05831189
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a treatment called RBX2660 (REBYOTA) for people with recurrent Clostridioides difficile infection. The treatment is made from healthy human stool bacteria and was given during a colonoscopy. The goal was to see if this delivery method is safe and works well. Forty-one adults took part, and the study also asked doctors and patients about their experience.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RBX2660 (REBYOTA), a live biotherapeutic product made from human stool bacteria
- What this could lead to
- If it works, this could offer a new way to deliver a proven treatment for recurrent C. diff infection, making it easier for patients to receive it during a routine colonoscopy.
- What could go wrong
- This is a small, single-arm trial with only 41 participants, so results may not apply to everyone. The treatment is already approved for other delivery methods, but colonoscopy delivery may have different risks or lower effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION RECURRENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ferring Investigational Site
North Little Rock, Arkansas, 72117, United States
-
Ferring Investigational Site
Camarillo, California, 93012, United States
-
Ferring Investigational Site
Hamden, Connecticut, 06518, United States
-
Ferring Investigational Site
Idaho Falls, Idaho, 83404, United States
-
Ferring Investigational Site
Gurnee, Illinois, 60031, United States
-
Ferring Investigational Site
Shreveport, Louisiana, 71105, United States
-
Ferring Investigational Site
Plymouth, Minnesota, 55446, United States
-
Ferring Investigational Site
Rochester, Minnesota, 55905, United States
-
Ferring Investigational Site
Cleveland, Ohio, 44195, United States
-
Ferring Investigational Site
Oklahoma City, Oklahoma, 73102, United States
-
Ferring Investigational Site
Burke, Virginia, 22015, United States
-
Ferring Investigational Site
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.